613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I

HEM ismart An international proof of concept therapeutic stratification trial of molecular anomalies in relapsed or refractory hematological malignancies in children

Cytopenias and infectious complications following CD19 directed CAR T cell therapy in patients with B ALL A single center retrospective analysis

Blinatumomab and ponatinib vs hyper CVAD and ponatinib in patients with Philadelphia chromosome positive acute lymphoblastic leukemia A propensity score analysis

Phase II Results of ECOG ACRIN EA9152 A multicenter study of liposomal vincristine L VCR or vincristine sulfate VCR and venetoclax VEN in relapsed or refractory acute lymphoblastic leukemia ALL and lymphoblastic lymphoma LL

Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10 4 or higher

Results of POLARIS 1 a global Phase 3 study Part A Olverembatinib combined with low intensity chemotherapy in patients with newly diagnosed ND Philadelphia chromosome positive Ph acute lymphoblastic leukemia ALL

Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B cell acute lymphoblastic leukemia Long term follow up from a phase 2 Study

A real world multi institution experience of standard vs alternative dosing of inotuzumab ozogamicin for Relapsed Refractory pediatric B cell acute lymphoblastic leukemia

Efficacy and safety of inotuzumab ozogamicin combined with venetoclax and dexamethasone in relapsed refractory B cell acute lymphoblastic leukemia R R B ALL

Daratumumab and venetoclax based combined regimen for relapsed refractory T lymphoblastic leukemia lymphoma

The addition of inotuzumab ozogamicin to frontline hyper CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B cell acute lymphoblastic leukemia Four year follow up of a phase 2 study

Hyper CVAD versus hyper CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome negative acute lymphoblastic leukemia A propensity score analysis

An updated UK real world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

Efficacy of short course versus standard course blinatumomab in patients with relapsed refractory or MRD positive B cell acute lymphoblastic leukemia

Front line consolidation with CAR t therapy in newly diagnosed adult ph negative b acute lymphoblastic leukemia Results from a prospective phase 2 study